Spots Global Cancer Trial Database for An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid Tumors
Official Title: An Open-Label Phase I/IIa Study of Intravenous BAL101553 in Adult Patients With Advanced Solid Tumors
Study ID: NCT01397929
Conditions
Interventions
Study Description
Brief Summary: First in human, open-label, sequential dose escalation and expansion study of intravenous BAL101553 in adult patients with advanced solid tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Royal Marsden Hospital, Sutton, Surrey, United Kingdom
University College London NHS Foundation Trust, London, , United Kingdom
Sir Bobby Robson Cancer Trials Research Centre; Northern Centre for Cancer Care, Newcastle upon Tyne, , United Kingdom
Contact Details
Name: Marc Engelhardt, MD
Affiliation: Basilea Pharmaceutica International Ltd
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
